CC-5013 is a potent analog of thalidomide that exerts a broad spectrum of pharmacologic, antiangiogenic, and immunologic effects. This is a dose-escalation trial of CC-5013 administered orally once daily for 21 days followed by a 7 day rest period to children with recurrent, refractory or progressive CNS tumors.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010585-03
Application #
7338766
Study Section
(NOB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code